IOVA

Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.

Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expected to last into 2029. Amtagvi's market-leading durability and expanding treatment center network support its competitive positioning despite intense oncology competition.

Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC opportunity appeared overestimated based on Q2 call signals. Recent NSCLC data showed a 24.6% ORR across 69 evaluable patients, slightly below the prior interim readout.

Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.

Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jen Saunders Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen Roche - Chief Financial Officer Daniel Kirby - Chief Commercial Officer Noah Berkowitz - Chief Medical Officer Raj Puri - Chief Regulatory Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Kuan-Hung Lin - Wells Fargo Securities, LLC, Research Division Nicholas Lorusso - TD Cowen, Research Division Joshua Korsen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the Iovance Biotherapeutics Third Quarter 2026 Conference Call.

Iovance Biotherapeutics NASDAQ: IOVA reported record third-quarter revenue of approximately $122 million, up 80% from a year earlier, as sales of its melanoma treatment AMTAGVI surpassed $100 million in a quarter for the first time.

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.25 per share a year ago.

Total Revenue Increased  ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous Metastatic Non-Small-Cell Lung Cancer (mNSCLC) 59.1% ORR in Biomarker-Selected mNSCLC Subgroup with POSITILITY Trial Underway 55.6% ORR in Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS) with SARATOGA Registrational Trial Underway PHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter 2026 financial results, business achievements, and corporate updates. “Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand,” said Frederick Vogt, Ph.D.

IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.

Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript